Top

Published in:

01-12-2013 | Original Communication

Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson’s disease and controls

Authors: Megan K. Herbert, H. Bea Kuiperij, Bastiaan R. Bloem, Marcel M. Verbeek

Published in: Journal of Neurology | Issue 12/2013

Abstract

The neurochemical abnormalities underlying vascular parkinsonism (VP) have not been well characterised. A better understanding may help to optimize pharmacological interventions. Since VP patients generally have a poorer response to l-Dopa than Parkinson’s disease (PD) patients, we investigated whether levels of relevant CSF neurotransmitter metabolites may be differentially altered in VP and PD and assessed the potential of neurotransmitter metabolites as biomarkers. We compared CSF levels of homovanillic acid (HVA), 5-hydroxyindolacetic acid, and 3-methoxy-4-hydroxyphenylethyleneglycol, in 16 VP patients, 57 PD patients and 60 non-neurological controls. We found that levels of HVA were reduced in PD compared with both VP and controls but did not differ significantly between VP and controls indicating that dopamine deficiency was less pronounced in VP.

Available only for authorised users

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedCrossRef

Zijlmans JCM, Daniel SE, Hughes AJ, Révész T, Lees AJ (2004) Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord 19:630–640PubMedCrossRef

Aerts MB, Esselink RAJ, Post B, van de Warrenburg BPC, Bloem BR (2012) Improving the diagnostic accuracy in parkinsonism: a three-pronged approach. Pract Neurol 12:77–87PubMedCrossRef

Antonini A, Vitale C, Barone P, Cilia R, Righini A, Bonuccelli U et al (2012) The relationship between cerebral vascular disease and parkinsonism: the VADO study. Parkinsonism Rel Disord 18:775–780CrossRef

Chang CM, Yu YL, Ng HK, Leung SY, Fong KY (1992) Vascular pseudoparkinsonism. Acta Neurol Scand 86:588–592PubMedCrossRef

Zijlmans JCM, Thijssen HOM, Vogels OJM, Kremer HPHMP, Poels PJE, Schoonderwaldt HC et al (1995) MRI in patients with suspected vascular parkinsonism. Neurology 45:2183–2188PubMedCrossRef

van Zagten M, Lodder J, Kessels F (1998) Gait disorder and parkinsonian signs in patients with stroke related to small deep infarcts and white matter lesions. Mov Disord 13:89–95PubMedCrossRef

Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E et al (2009) Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms. Lancet Neurol 8:1128–1139PubMedCrossRef

Halliday GM, Blumbergs PC, Cotton RGH, Blessing WW, Geffen LB (1990) Loss of brainstem serotonin- and substance P-containing neurons in Parkinson’s disease. Brain Res 510:104–107PubMedCrossRef

10.

Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128:1314–1322PubMedCrossRef

11.

Constantinescu R, Richard I, Kurlan R (2007) Levodopa responsiveness in disorders with parkinsonism: a review of the literature. Mov Disord 22:2141–2148PubMedCrossRef

12.

Gupta D, Kuruvilla A (2011) Vascular parkinsonism: what makes it different? Postgrad Med J 87:829–836PubMedCrossRef

13.

Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125:861–870PubMedCrossRef

14.

Winikates J, Jankovic J (1999) Clinical correlates of vascular parkinsonism. Arch Neurol 56:98–102PubMedCrossRef

15.

Critchely M (1929) Arteriosclerotic parkinsonism. Brain 52:23–83CrossRef

16.

FitzGerald PM, Jankovic J (1989) Lower body parkinsonism: evidence for vascular etiology. Mov Disord 4:249–260PubMedCrossRef

17.

Hoehn MMMD, Yahr MDMD (2001) Parkinsonism: onset, progression, and mortality. Neurology 57(10):S11–S26PubMed

18.

Fahn S, Elton RL (1987) Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB (eds) Recent developments in Parkinson’s Disease. Macmillan Healthcare Information, Florham Park, pp 153–163

19.

Brautigam C, Wevers RA, Jansen RJ, Smeitink JA, de Rijk-van Andel JF, Gabreels FJ, Hoffmann GF (1998) Biochemical hallmarks of tyrosine hydroxylase deficiency. Clin Chem 44:1897–1904PubMed

20.

Abdo WF, van de Warrenburg BPC, Munneke M, van Geel WJA, Bloem BR, Kremer HPH et al (2006) CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia. Neurology 67:474–479PubMedCrossRef

21.

Tohgi H, Abe T, Saheki M, Yamazaki K, Murata T (1997) Concentration of catecholamines and indoleamines in the cerebrospinal fluid of patients with vascular parkinsonism compared to Parkinson’s disease patients. J Neural Transm 104:441–449PubMedCrossRef

22.

Espino A, Ambrosio S, Bartrons R, Bendahan G, Calopa M (1994) Cerebrospinal monoamine metabolites and amino acid content in patients with parkinsonian syndrome and rats lesioned with MPP+. J Neural Transm 7:167–176CrossRef

23.

Hartikainen P, Soininen H, Reinikainen KJ, Sirviö J, Soikkeli R, Riekkinen PJ (1991) Neurotransmitter markers in the cerebrospinal fluid of normal subjects effects of aging and other confounding factors. J Neural Transm 84(1–2):103–117CrossRef

24.

Nilsson C, Stahlberg F, Thomsen C, Henriksen O, Herning M, Owman C (1992) Circadian variation in human cerebrospinal fluid production measured by magnetic resonance imaging. Am J Physiol Regul Integr Comp Physiol 262(1):R20–R24

25.

de Laat KF, van Norden AGW, Gons RAR, van Uden IWM, Zwiers MP, Bloem BR et al (2012) Cerebral white matter lesions and lacunar infarcts contribute to the presence of mild parkinsonian signs. Stroke 43:2574–2579PubMedCrossRef

26.

Eisenhofer G, Kopin IJ, Goldstein DS (2004) Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 56:331–349PubMedCrossRef

27.

Zijlmans JCM, Katzenschlager R, Daniel SE, Lees AJL (2004) The l-Dopa response in vascular parkinsonism. J Neurol Neurosurg Psychiatry 75:545–547PubMedCrossRef

28.

Glass PG, Lees AJ, Bacellar A, Zijlmans J, Katzenschlager R, Silveira-Moriyama L (2012) The clinical features of pathologically confirmed vascular parkinsonism. J Neurol Neurosurg Psychiatry 83:1027–1029PubMedCrossRef

29.

Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang L-J, Guttman M et al (2008) Preferential loss of serotonin markers in caudate versus putamen in Parkinson’s disease. Brain 131:120–131PubMed

30.

Reed MC, Best JA, Nijhout HF (2012) Mathematical insights into the effects of levodopa. Front Integr Neurosci 6:21PubMedCrossRef

31.

Navailles S, De Deurwaerdere P (2012) Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson’s disease. Mol Neurobiol 45:173–185PubMedCrossRef

Title: Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson’s disease and controls
Authors: Megan K. Herbert
H. Bea Kuiperij
Bastiaan R. Bloem
Marcel M. Verbeek
Publication date: 01-12-2013
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 12/2013
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-013-7126-5

At a glance: The STEP trials

Springer Medicine

Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson’s disease and controls

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2013

Selective hyposmia in Parkinson’s disease?

Ambulatory activity in incident Parkinson’s: more than meets the eye?

Multiple sclerosis in the Arabian Gulf countries: a consensus statement

Optic neuropathy in Behçet’s syndrome

Olfactory loss as a supporting feature in the diagnosis of Parkinson’s disease: a pragmatic approach

Juvenile parkinsonism as an initial manifestation of gliomatosis cerebri